IMNM (Immunome) Debt-to-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunome Debt-to-Asset?

Immunome's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.26 Mil. Immunome's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.46 Mil. Immunome's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $256.90 Mil. Immunome's debt to asset for the quarter that ended in Sep. 2024 was 0.01.

Immunome Debt-to-Asset Historical Data

The historical data trend for Immunome's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Debt-to-Asset Chart

Immunome Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.11

0.01

Immunome Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.01	0.01	0.01	0.01

Competitive Comparison of Immunome's Debt-to-Asset

For the Biotechnology subindustry, Immunome's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immunome's Debt-to-Asset falls into.

Immunome Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immunome's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.31	+	1.34)	/	148.54
	=	0.01

Immunome's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.257	+	2.464)	/	256.898
	=	0.01

Immunome (NAS:IMNM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immunome Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Immunome's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011

Website

https://www.immunome.com

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Executives

Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Robert Lechleider	officer: Chief Medical Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett	officer: SVP Operations	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Jean Jacques Bienaime	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Higgins	officer: Chief Scientific Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas	director, other: See remarks	1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner	officer: Chief Strategy Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson	officer: Chief Technology Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp	director, 10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast	director
Michael Lefenfeld	director	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma	director, officer: President and CEO	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim	director	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019